Thermo Fisher Scientific (BSP:TMOS34) Piotroski F-Score: 6 (As of Jun. 25, 2026) — 14% Below Median


BSP:TMOS34 Thermo Fisher Scientific Inc BSP:TMOS34
74 GF Score
Price R$53.25
GF Value R$63.08
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Thermo Fisher Scientific Piotroski F-Score?

Thermo Fisher Scientific BSP:TMOS34 +7.04% 74 Piotroski F-Score is 6 as of Jun. 25, 2026, which is 14% below its 10-year median of 7.00. GuruFocus rates BSP:TMOS34 with a GF Score™ of 74/100 and a GF Value™ of R$63.08 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 211 Medical Diagnostics & Research companies, Thermo Fisher Scientific ranks better than 79.15% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Thermo Fisher Scientific has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Thermo Fisher Scientific's Piotroski F-Score or its related term are showing as below:

BSP:TMOS34' s Piotroski F-Score Range Over the Past 10 Years
Min: 4   Med: 7   Max: 9
Current: 6

During the past 13 years, the highest Piotroski F-Score of Thermo Fisher Scientific was 9. The lowest was 4. And the median was 7.

Thermo Fisher Scientific  (BSP:TMOS34) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Thermo Fisher Scientific Piotroski F-Score Related Terms


Thermo Fisher Scientific Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Thermo Fisher Scientific's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Thermo Fisher Scientific Piotroski F-Score Chart

Thermo Fisher Scientific Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.00 5.00 5.00 7.00 7.00

Thermo Fisher Scientific Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.00 7.00 6.00 7.00 6.00

BSP:TMOS34 vs DHR, IDXX, A: Piotroski F-Score Comparison

For the Diagnostics & Research subindustry, Thermo Fisher Scientific's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Thermo Fisher Scientific Piotroski F-Score vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Thermo Fisher Scientific's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Thermo Fisher Scientific's Piotroski F-Score falls into.


BSP:TMOS34
74GF Score
Thermo Fisher Scientific Inc BSP:TMOS34
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was 8967.559 + 8666.608 + 10714.995 + 8634.07 = R$36,983 Mil.
Cash Flow from Operations was 7758.574 + 12007.757 + 18860.355 + 6233.683 = R$44,860 Mil.
Revenue was 60194.113 + 59647.286 + 66641.375 + 57551.748 = R$244,035 Mil.
Gross Profit was 24445.886 + 24578.629 + 27338.513 + 23167.128 = R$99,530 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(570287.982 + 561401.334 + 552496.26 + 601998.305 + 592414.318) / 5 = R$575719.6398 Mil.
Total Assets at the begining of this year (Mar25) was R$570,288 Mil.
Long-Term Debt & Capital Lease Obligation was R$209,555 Mil.
Total Current Assets was R$116,704 Mil.
Total Current Liabilities was R$76,462 Mil.
Net Income was 8337.683 + 9026.614 + 11164.83 + 8677.457 = R$37,207 Mil.

Revenue was 56774.88 + 58689.604 + 69520.895 + 59676.948 = R$244,662 Mil.
Gross Profit was 23413.377 + 23967.598 + 29419.022 + 24385.553 = R$101,186 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(483513.681 + 530509.306 + 555795.759 + 593755.421 + 570287.982) / 5 = R$546772.4298 Mil.
Total Assets at the begining of last year (Mar24) was R$483,514 Mil.
Long-Term Debt & Capital Lease Obligation was R$180,632 Mil.
Total Current Assets was R$134,613 Mil.
Total Current Liabilities was R$75,857 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Thermo Fisher Scientific's current Net Income (TTM) was 36,983. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Thermo Fisher Scientific's current Cash Flow from Operations (TTM) was 44,860. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=36983.232/570287.982
=0.0648501

ROA (Last Year)=Net Income/Total Assets (Mar24)
=37206.584/483513.681
=0.07695043

Thermo Fisher Scientific's return on assets of this year was 0.0648501. Thermo Fisher Scientific's return on assets of last year was 0.07695043. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Thermo Fisher Scientific's current Net Income (TTM) was 36,983. Thermo Fisher Scientific's current Cash Flow from Operations (TTM) was 44,860. ==> 44,860 > 36,983 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=209555.302/575719.6398
=0.36398845

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=180631.597/546772.4298
=0.33035974

Thermo Fisher Scientific's gearing of this year was 0.36398845. Thermo Fisher Scientific's gearing of last year was 0.33035974. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=116703.754/76461.982
=1.52629779

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=134612.862/75857.209
=1.77455596

Thermo Fisher Scientific's current ratio of this year was 1.52629779. Thermo Fisher Scientific's current ratio of last year was 1.77455596. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Thermo Fisher Scientific's number of shares in issue this year was 17904. Thermo Fisher Scientific's number of shares in issue last year was 18192. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=99530.156/244034.522
=0.40785277

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=101185.55/244662.327
=0.41357225

Thermo Fisher Scientific's gross margin of this year was 0.40785277. Thermo Fisher Scientific's gross margin of last year was 0.41357225. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=244034.522/570287.982
=0.42791454

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=244662.327/483513.681
=0.50600911

Thermo Fisher Scientific's asset turnover of this year was 0.42791454. Thermo Fisher Scientific's asset turnover of last year was 0.50600911. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+0+1+0+0+1+0+0
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Thermo Fisher Scientific has an F-score of 4 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 6 mean?
Thermo Fisher Scientific (BSP:TMOS34) has a Piotroski F-Score of 6 as of Jun. 25, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Thermo Fisher Scientific and its competitors. This is 14% below median its historical median of 7.00. Over the past decade, Thermo Fisher Scientific's Piotroski F-Score has ranged from 4.00 to 9.00. According to the industry distribution chart, Thermo Fisher Scientific ranks #44 out of 211 companies in the Medical Diagnostics & Research industry, placing it in the top 20.9%.
Is Thermo Fisher Scientific's Piotroski F-Score too high?
Thermo Fisher Scientific's current Piotroski F-Score of 6 is 14% below median its 10-year median of 7.00. Over the past 10 years, this metric has ranged from a low of 4.00 to a high of 9.00. The Medical Diagnostics & Research industry median Piotroski F-Score is 5.00. Thermo Fisher Scientific's value of 6 is 20% above this industry median. Based on the distribution chart, Thermo Fisher Scientific ranks #44 out of 211 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Thermo Fisher Scientific has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Thermo Fisher Scientific's Piotroski F-Score compare to DHR and IDXX?
According to the Medical Diagnostics & Research industry distribution chart, Thermo Fisher Scientific ranks #44 out of 211 companies for Piotroski F-Score. This places Thermo Fisher Scientific in the top 21% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 5.00. Thermo Fisher Scientific's value of 6 is 20% above this benchmark. Historically, Thermo Fisher Scientific's own Piotroski F-Score has ranged from 4.00 to 9.00 over the past decade. While the company's 10-year median is 7.00 vs. the industry median of 5.00, Thermo Fisher Scientific has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Medical Diagnostics & Research company?
The median Piotroski F-Score among Medical Diagnostics & Research companies is 5.00, based on 211 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Thermo Fisher Scientific's current Piotroski F-Score of 6 is 20% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Thermo Fisher Scientific and its competitors. For the Medical Diagnostics & Research industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Thermo Fisher Scientific's current Piotroski F-Score is 6, which is 14% below median its own 10-year median of 7.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Thermo Fisher Scientific stock overvalued right now?
Based on GuruFocus' analysis, Thermo Fisher Scientific (BSP:TMOS34) is currently considered Modestly Undervalued. The stock's GF Value™ is R$63.08, compared to a current price of R$53.25 — trading 15.6% below its estimated fair value. The current Piotroski F-Score is 6, which is 14% below median its 10-year median of 7.00 and 20% above the Medical Diagnostics & Research industry median of 5.00. Thermo Fisher Scientific's overall GF Score™ is 74/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Thermo Fisher Scientific (BSP:TMOS34), the current Piotroski F-Score is 6 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Thermo Fisher Scientific (BSP:TMOS34) Overvalued in 2026?

Based on GuruFocus' analysis, Thermo Fisher Scientific stock appears to be undervalued. The current stock price of R$53.25 is trading 15.6% below its estimated GF Value™ of R$63.08. GuruFocus considers Thermo Fisher Scientific to be Modestly Undervalued.

Key valuation signals for BSP:TMOS34:

  • Piotroski F-Score: 6 (14% below median its 10-year median of 7.00)
  • GF Value™: R$63.08 vs. price of R$53.25 (15.6% below fair value)
  • GF Score™: 74/100 with 5 warning signs
  • Industry Position: 20% above the Medical Diagnostics & Research median (#44 of 211)

No single metric tells the full story. See the BSP:TMOS34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Thermo Fisher Scientific Business Description

Address 168 Third Avenue, Waltham, MA, USA, 02451
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year-end 2025 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (the remainder).
74GF Score

Get the complete analysis for BSP:TMOS34

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$53.25
Price
R$63.08
GF Value